Q-omics provides the consensus-scored DIO3 profile across patient tissues and cancer cell-line models. DIO3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DIO3 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, DIO3 RNA expression shows 13,180 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, BLCA, and GBM as cancer lineages where DIO3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DIO3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DIO3 survival associations across molecular data types. DIO3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DIO3 RNA expression–survival associations across cancer types. High DIO3 expression shows unfavorable associations in KIRP, but favorable associations in ESCA, BRCA, UCS, READ and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DIO3 RNA expression.
This table summarizes DIO3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for DIO3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DIO3 shows lower tumor expression in BLCA, THCA, KICH, LUAD, UCEC and BRCA. The BLCA box plot shows higher DIO3 RNA expression in normal versus tumor tissue (log2 FC = −2.038, t-test p < 0.001).
This table shows molecular features associated with DIO3 in patient tissues and cancer cell lines. In patient samples, DIO3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DIO3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
